Insulin-like growth factor binding protein-3 in patients with liver cirrhosis.
Aim of the study was to evaluate serum levels of insulin-like growth factor binding protein-3 in patients with liver cirrhosis and to compare serum IGFBP-3 levels with other liver function tests. Fifty-one patients with liver cirrhosis were selected for our study. We measured IGFBP-3 (1.67+/-1.06 mg/l, mean+/-SD), albumin (32+/-8 g/l), prealbumin (0.22+/-0.14 g/l), AST (2.29+/-2.38 microkat/l), ALT (2.11+/-4.83 microkat/l) and cholinesterase (mean 78.6+/-45.2 microkat/l) in the serum. There was a significant positive correlation of serum IGFBP-3 with serum albumin and serum cholinesterase. The correlation coefficient was much lower between serum IGFBP-3 and serum prealbumin. There was no significant correlation between serum AST, ALT and IGFBP-3. Serum IGFBP-3 proves to be a better marker for the hepatic synthetic capacity than serum albumin or cholinesterase.
Sídlová
K
K
Department of Clinical Biochemistry and Pathobiochemistry, Second Faculty of Medicine, Charles University and Faculty Hospital Motol, Prague, Czech Republic. katerina.sidlova@email.cz
Pechová
M
M
Kotaska
K
K
Průsa
R
R
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D000704:Analysis of Variance; D001219:Aspartate Aminotransferases / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000503:physiopathology*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011228:Prealbumin / Q000032:analysis; D012709:Serum Albumin / Q000032:analysis; D013223:Statistics as Topic
D015415:Biomarkers; D018972:Insulin-Like Growth Factor Binding Protein 3; D011228:Prealbumin; D012709:Serum Albumin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase